;   Medical Translation Insight: Ovid partnership brings education to device, drug professionals - ForeignExchange Translations

Partnership with Ovid aids device, drug professionals - medical translation
Over the past ten years, our audio conference business has served thousands upon thousands of regulatory, clinical, quality and translation professionals with hundreds of educational seminars. And now we are taking a huge leap forward in our mission to provide distance learning to drug and device professionals: Effective immediately, the FXConferences catalog is available through Ovid!

Ovid, of course, is the global information solutions provider that helps researchers, librarians, clinicians, and other healthcare professionals find important medical information so that they can make critical decisions to improve patient care, enhance ongoing research, and fuel new discoveries. As part of Wolters Kluwer Health, Ovid has a platform and network that makes it easy for drug and device companies to subscribe to relevant content.

FXConferences and Ovid are cooperating across a number of dimensions:
  • 10 collections available, each featuring 10 audio-recorded events delivered by international expert speakers
  • Each event includes a 45-minute audio presentation and a 15-minute Q&A session
  • Collections available with or without transcripts
  • Topics are relevant to teams across the entire organization and practical content can be applied to their daily work in R&D, product development, clinical trials, quality assurance, and regulatory affairs
  • Users can access content in multiple ways: during a team meeting, in the office, or on the daily commute
For more details, take a look at Ovid's announcement [PDF] or the Ovid web site.

In addition to providing high-value educational content, ForeignExchange Translations offers drug and device companies specialized medical translation solutions.


Post a Comment


Services | Resources | Company | Contact Us | Blog | Home

(c) Copyright 2010, ForeignExchange Translations, Inc.